Navigation Links
Debiopharm in Medical News

Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories

PARIS and LAUSANNE, Switzerland, Oct. 31 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN) and Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions today announced the extension of their agreement, whereby Ips...

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA

...e TRELSTAR(R) NDA was prepared in cooperation with debiopharm Group, a Swiss-based global biopharmaceutical grou...bout TRELSTAR (R) TRELSTAR(R), developed by debiopharm Group and marketed by Watson, administers a synthe...e at http://www.watson.com . About debiopharm Group ...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

... of Celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 debiopharm Releases Phase Ib Results of Debio 025 II-59 Nabi Biopharmaceuticals Starts Proof-Of-Concept Trial for Civacir II-60 Peregrine Announces Posit...

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

...e for men and their physicians and will be a significant addition to our expanding urology portfolio." About TRELSTAR(R) TRELSTAR(R), developed by debiopharm Group, a Swiss biopharmaceutical development specialist, and marketed by Watson Pharma, Inc., is a synthetic hormone known as a luteinizing hormone re...

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

... LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- debiopharm Group (Debiopharm), a global independent biopharma...d Rolland-Yves Mauvernay, president and founder of debiopharm Group. "This demonstrates our ability to work effe...y marketed by Watson Pharmaceuticals, Inc. About debiopharm Group ...

Investigational drug tested for preventing muscle fiber death in muscular dystrophy

...ilin D and blocks cell death in a number of situations, the drug does not suppress the immune system or block calcineurin. The drug is manufactured by debiopharm S.A. of Lausanne, Switzerland, which provided Debio-025 for use in the study. The researchers also found their study may have implications beyond ...

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology

...rier, currently in late preclinical development by debiopharm for use in oncology. Phase I clinical studies are ... the terms of the agreement: - NanoCarrier grants debiopharm an exclusive license, with the right to sublicense...in Polymeric Micelle worldwide excluding Japan. - debiopharm will provide NanoCarrier exclusively with the star...

Ranbaxy to Market Debiopharm's New Drug in India

...t with Swiss biopharmaceutical development company debiopharm Group to// market its new gastro-enterology drug. ...is presently undergoing Phase III clinical trials. debiopharm expects to file Sanvar for approval in the US in f...uarter of 2007. "We are glad to partner with debiopharm in the gastro-enterology area and shall work towar...
Debiopharm in Medical Technology

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND

LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that the first healthy elderly subjects have been randomised in a clinical bi...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...diabetes. Under the terms of the agreement, debiopharm shall pay Mercury for continued research and devel...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group." "This alliance with debiopharm represents important validation of Mercury's techn...

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

... LAUSANNE, Switzerland, June 23 /PRNewswire/ -- debiopharm Group (Debiopharm), a Swiss-based global biopharma...). There are also fewer side effects. About debiopharm Group debiopharm Group is a Swiss-based global biopharmaceutical gr...

Clinical Update - Debio 025 in Hepatitis C

... LAUSANNE, Switzerland, April 28 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "We are making it our mission to find a cur... About the phase IIa triple therapy study debiopharm investigated different dosing regimens of Debio 02...

Clinical Update - Debio 025 in Hepatitis C

... LAUSANNE, Switzerland, January 26 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "With over 170 million people infect...we hope to address," added Kamel Besseghir, CEO of debiopharm S.A. About Debio 025 Debio 025 is a ...

Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding

... debiopharm Submits Response to the FDA LAUSANNE, Switzerland, November 4 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, president and founder of debiopharm Group. "Last summer, we completed a confirmatory...

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

...AUSANNE, Switzerland, September 25 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...enience and comfort," said Kamel Besseghir, CEO of debiopharm S.A. "Furthermore, upon approval, our newly built ... licensee sales are in excess of US $400M. About debiopharm Group ...

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment

...LAUSANNE, Switzerland, September 2 /PRNewswire/ -- debiopharm Group (Debiopharm), a global independent biopharma... standard therapies," said Kamel Besseghir, CEO of debiopharm S.A. About debiopharm Group ...
Debiopharm in Biological Technology

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the developme...

Japanese Cancer Association and Debiopharm Honour Japanese Research

Professors Ichijo and Mano Receive 2008 JCA-Mauvernay Award LAUSANNE, Switzerland, October 29 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, presented Professors Hideno...

Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award

LAUSANNE, Switzerland, October 8 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented Professors Minoru Toyota and Keiichi Nakayama with the 2007 JCA-Mauvernay Award for their outstand...

The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstan...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

...tic drug. Under the terms of the agreement, debiopharm and MSM haveformed a partnership to select antibod... completion of the discovery phase, MSM will grant debiopharm a worldwide exclusive licence for the development ...and Asia. MSM will receive milestone payments from debiopharm during the development of the product, as well as ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...2 Monoclonal Antibodies II-52 Vaccines II-52 Radioactive Monoclonal Antibodies II-52 5. Drug Approvals and Clinical Studies II-53 debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment II-53 Algeta to Start Clinical Study of Alpharadin in HRPC II-53 ...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

...our drug. Under the terms of the agreement, debiopharm shall pay Moffitt an up-front fee, as well as pred...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "Being able to de-activate a key signalling...artment of Drug Discovery at Moffitt. About debiopharm Group ...

Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation

...atories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, debiopharm and Transgene. Caprion also has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectio...

Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions

...europathic pain. Under the terms of the agreement, debiopharm will make an up-front payment to Pharmaleads, as w...therapeutic area of chronic pain management to the debiopharm product portfolio. There is currently an unmet med...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "This exclusive licence agreement is...

Covance Purchases Equity Stake in Caprion Proteomics

...atories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, debiopharm and Transgene. Caprion also has been awarded two major 5-year Biodefense proteomics research contracts in infectious disease with the NIH-NIAID, and w...
Other Tags
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Difass USA, ... can help pass those long, stressful days at work is knowing that there is ... as laid back and stress free as imagined. Planning for a vacation can be ...
(Date:7/7/2015)... ... July 07, 2015 , ... Seattle-based ... have merged to form Camber Collective. Camber Collective provides strategic advisory services ... SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in customer insights, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased ... 304, Melville, New York 11747. The new facility is a state of the ... lines. , Richard Quadrino, the firm's CEO and founder, said, "We are pleased to ...
(Date:7/7/2015)... ... July 07, 2015 , ... At the end of June Pacific Prime Renewals team in ... . This initiative, spearheaded by the Renewals Manager, Danielle Cotton, aims to not only reduce ... On this initiative Cotton explained, “We send anything between 300 and 600 pieces of paper ...
(Date:7/7/2015)... ... 2015 , ... Healthpointe is proud to announce the addition of ... pain management specialist, will be evaluating and treating patients with orthopedic complaints, such as ... his Bachelor of Science in Biology from the University of the East, Manila, Dr. ...
Breaking Medicine News(10 mins):Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
Other Contents